QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

CGEM

QT77Cullinan Therapeutics, Inc.
NASDAQ·Healthcare·Medical - Pharmaceuticals·USA
Latest market price
15.03
+0.59+4.09%
OverviewShort InterestFilings
CGEMQT77Cullinan Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
15.03+4.09%
TA
Loading chart...
Screen all →
ONC+2.84%$270.15AVLN+7.30%$31.45LLY-1.21%$1098.57JNJ-2.48%$228.39ABBV-2.08%$216.63UNH+0.36%$400.96NVS-2.52%$147.08MRK-1.36%$113.87
Snapshot
Index-P/E-EPS (ttm)-
Insider Own-
Shs Outstand61.46M
Perf Week15.79%
Market Cap887.45MForward P/E-EPS next Y-2.41Insider Trans-0.11%Shs Float-Perf Month5.99%
Enterprise Value814.76MPEG0.20EPS next Q-0.80Inst Own-Short Float-Perf Quarter14.91%
Income-229495480.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y47.06%
Sales-P/B2.33EPS next Y20.51%ROA-54.85%Short Interest-Perf YTD45.22%
Book/sh5.96P/C-EPS next 5Y-ROE-51.45%52W High16.74 -10.22%Perf Year80.65%
Cash/sh5.73P/FCF-EPS past 3/5Y-ROIC-65.21%52W Low5.68 164.61%Perf 3Y-
Dividend Est.-EV/EBITDA-3.69Sales past 3/5Y-Gross Margin0.00%Volatility5.31% 5.62%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-8.04%Oper. Margin0.00%ATR (14)1.17Perf 10Y-
Dividend Ex-Date-Quick Ratio10.28Sales Y/Y TTM-Profit Margin0.00%RSI (14)55.57Recom2.00
Dividend Gr. 3/5Y-Current Ratio10.28EPS Q/Q-1.35%SMA204.69%Beta1.63Target Price31.00
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA504.18%Rel Volume2.96Prev Close14.44
Employees111LT Debt/Eq0.00EarningsAug 06SMA20031.61%Avg Volume1.05MPrice15.03
IPO DateJan 08, 2021Option/ShortYes / YesEPS/Sales Surpr.10.27% -Net Debt/EBITDA0.33Volume3,114,453Change4.09%
Analyst Ratings
DateActionAnalystRatingTarget
May-08-26ReiteratedWedbushOutperform$36 → $37
Apr-28-26ReiteratedH.C. Wainwright$27 → $30
Mar-11-26ReiteratedWedbushOutperform$34 → $36
Mar-10-26ReiteratedStifel Nicolaus$28
Feb-02-26InitiatedGuggenheimBuy$30
Jan-08-26ReiteratedH.C. Wainwright$26 → $27
Jan-08-26ReiteratedMorgan StanleyOverweight$28 → $30
Dec-09-25ReiteratedWedbushOutperform$34
Nov-24-25ReiteratedBTIGBuy$32 → $38
Nov-20-25ReiteratedNew Street$24 → $26
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit000
Selling, General and Administrative Excl. Other545442
Research and Development187143148
Other Operating Expense101
Operating Income-242-197-191
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-22-290
Net Income Before Taxes-220-167-169
Income Taxes00-14
Consolidated Net Income-220-167-153
Net Income From Continuing Operations-220-168-155
Net Income-220-167-153
EPS (Recurring)-3.72-3.11-3.69
EPS (Basic, Before Extraordinaries)-3.72-3.11-3.69
EPS (Diluted)-3.72-3.11-3.69
EBITDA-220-167-190
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin———
Operating Margin———
Net Margin———
Shares Outstanding595442
Market Capitalization611——
Operating Lease Expense
———
Insider Trading Volume
$15.76$14.37$12.98$11.60$10.21● Close Price0.00M3.33M6.66M9.99M13.32MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Michaelson JenniferChief Scientific OfficerMay 05 '26Sale14.628,000116,996166,844May 06 12:00 AM
Michaelson JenniferChief Scientific OfficerMay 05 '26Option Exercise4.308,00034,400174,844May 06 12:00 AM
Michaelson JenniferChief Scientific OfficerMar 05 '26Sale15.688,000125,440170,844Mar 09 12:00 AM
Michaelson JenniferChief Scientific OfficerMar 05 '26Option Exercise4.308,00034,400178,844Mar 09 12:00 AM
Michaelson JenniferChief Scientific OfficerFeb 25 '26Sale14.141,78025,169174,844Feb 26 12:00 AM
AHMED NADIMPresident and CEOFeb 24 '26Sale14.4713,515195,562390,803Feb 25 12:00 AM
Michaelson JenniferChief Scientific OfficerFeb 24 '26Sale14.473,60152,106176,624Feb 25 12:00 AM
Jones Jeffrey AlanChief Medical OfficerFeb 24 '26Sale14.474,58266,302159,968Feb 25 12:00 AM
SUMER JACQUELYN LChief Legal OfficerFeb 24 '26Sale14.473,60152,106128,089Feb 25 12:00 AM
Michaelson JenniferChief Scientific OfficerFeb 23 '26Sale13.991,75224,510180,225Feb 25 12:00 AM
Jones Jeffrey AlanChief Medical OfficerFeb 20 '26Sale13.624,98267,855164,550Feb 23 12:00 AM
Michaelson JenniferChief Scientific OfficerFeb 20 '26Option Exercise4.3016,00068,800189,977Feb 23 12:00 AM
Michaelson JenniferChief Scientific OfficerFeb 20 '26Sale14.0811,742165,366181,977Feb 23 12:00 AM
SUMER JACQUELYN LChief Legal OfficerFeb 20 '26Sale13.623,74250,966131,690Feb 23 12:00 AM
Fenton Mary KayChief Financial OfficerFeb 20 '26Sale13.624,39859,901126,380Feb 23 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR